InflaRx N.V. (NASDAQ: IFRX)
$1.67
-0.0100 ( -0.59% ) 8.9K
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Market Data
Open
$1.67
Previous close
$1.68
Volume
8.9K
Market cap
$98.34M
Day range
$1.65 - $1.70
52 week range
$1.14 - $4.30
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | Jan 25, 2024 |
6-k | Quarterly Reports | 31 | Jan 04, 2024 |
6-k | Quarterly Reports | 3 | Nov 06, 2023 |
6-k | Quarterly Reports | 5 | Nov 01, 2023 |
6-k | Quarterly Reports | 3 | Sep 11, 2023 |
6-k | Quarterly Reports | 3 | Aug 30, 2023 |
6-k | Quarterly Reports | 59 | Aug 10, 2023 |